RT journal article
T1 Response to glecaprevir/pibrentasvir in HIV/HCV-coinfected patients in clinical practice
A1 Gonzalez-Serna, Alejandro
A1 Corma-Gomez, Anaïs
A1 Téllez Pérez, Francisco de Paula
A1 Corona-Mata, Diana
A1 Rios-Villegas, María Jose
A1 Merino, Dolores
A1 Galera, Carlos
A1 Collado-Romacho, Antonio Ramon
A1 De Los Santos, Ignacio
A1 Cucurull, Josep
A1 Santos, Marta
A1 García-Martín, Sofía
A1 Rivero, Antonio
A1 Real, Luis Miguel
A1 Macias, Juan
A2 Medicina
AB Objectives: HIV infection has been associated with lower rates of sustained viral response (SVR) with direct-acting antivirals (DAAs). There are few data on glecaprevir/pibrentasvir (G/P) in HIV/HCV coinfection outside clinical trials. Methods: The HEPAVIR-DAA cohort, which recruits HIV/HCV-coinfected patients (NCT02057003) and the GEHEP-MONO cohort (NCT02333292), including HCV-monoinfected individuals, are two concurrent ongoing multicentre cohorts of patients receiving anti-HCV treatment. Patients starting G/P included in those cohorts were analysed. Overall SVR (ITT), discontinuations due to adverse effects, and dropouts were evaluated and compared between both cohorts. Results: Of the 644 patients who started G/P with evaluable SVR, 132 were HIV/HCV coinfected. Overall SVR rates were 487/512 (95.1%) in HCV-monoinfected patients versus 126/132 (95.5%) in HIV/HCV-coinfected patients (P = 1.000). One patient (0.8%) relapsed, and another (0.8%) discontinued treatment due to side effects. SVR to 8 or 12 weeks of treatment with G/P was similar in HIV/HCV-coinfected versus HCV-monoinfected patients. The main reason for not reaching SVR among HIV/HCV-coinfected patients was premature dropout linked to active drug use. Conclusions: G/P in HIV/HCV coinfection was highly effective and tolerable in clinical practice. SVR to 8 or 12 weeks of treatment with G/P was similar in HIV/HCV-coinfected compared with HCV-monoinfected patients but active drug use is still a barrier to reach HCV microelimination.
PB Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy
SN 1460-2091
YR 2023
FD 2023
LK http://hdl.handle.net/10498/32319
UL http://hdl.handle.net/10498/32319
LA eng
DS Repositorio Institucional de la Universidad de Cádiz
RD 13-nov-2026